Abstract:The surge of SARS-CoV-2 Omicron infection in most Chinese residents at the end of 2022 provided a unique opportunity to understand how the immune system responds to the Omicron infection in a population with limited contact to prior SARS-CoV-2 variants. Moreover, whether the prototype SARS-CoV-2 booster vaccination could help induce the antibody against Omicron variants? Here, we tested the level of IgG, IgA, and IgM specific to the prototype SARS-CoV-2 spike RBD (Receptor Binding Domain) from the collected blood samples from 636 individuals. Sequential inoculation of different vaccines showed higher IgG levels after infection. As the antibody level against Omicron BA.5, BF.7, and XBB 1.5 of the individuals has highly positive correlation with the antibody level against prototype SARS-CoV2, the IgG level specific to the prototype SARS-CoV-2 spike RBD could also represent the IgG level against Omicron variants. Furthermore, the 4th booster vaccination could induce a comparable antibody level against prototype, Omicron BA.5, BF.7, and XBB 1.5 variants in the patients with 2 or 3-dose vaccination and protect people from being infected. In conclusion, these data suggest that the prototype SARS-CoV-2 booster vaccination helps induce a high level of antibody against prototype, BA.5, BF.7, and XBB 1.5 variants after Omicron infection. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was funded by the SARS-CoV2 Research and Control Project 2020 (Jack Ma Foundation), National Natural Science Foundation of China (82000941 to D.T.), Fundamental Research Funds for the Central Universities (WK5290000001 to Y.C., WK5290000002 to Y.Yao.). The study was also supported by Anhui Postdoctoral Scientific Program (D.T.). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee of The First Affiliated Hospital of University of Science and Technology of China gave ethical approval for this work. Approval number: 2023-KY-001 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors. All data produced in the present work are contained in the manuscript.

Post-vaccination Omicron infections induce broader immunity across antigenic space than prototype mRNA COVID-19 booster vaccination or primary infection

Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice

Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines

Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history.

Primary Exposure to SARS-CoV-2 Variants Elicits Convergent Epitope Specificities, Immunoglobulin V Gene Usage and Public B Cell Clones

SARS-CoV-2 BA.1 Variant is Neutralized by Vaccine Booster–elicited Serum but Evades Most Convalescent Serum and Therapeutic Antibodies

Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without Vaccination.

Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern

SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents

Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination

A survey and antibody test following the surge of SARS-CoV-2 Omicron infection in China

Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID‐19 Booster Vaccines and Recent SARS‐CoV‐2 Omicron Variant Infections

SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster

Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations

Limited Cross-Variant Immunity from SARS-CoV-2 Omicron Without Vaccination

Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1

Mucosal immunity against SARS-CoV-2 variants of concern including Omicron following vaccination

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing

Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population

Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations